Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders?PRNewsWire · Aug 4, 2026
The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—NRIM, NEUP, SAFT, and RMAXGlobeNewsWire · Jul 30, 2026
Are CBZ, SAFT, NEUP Obtaining Fair Deals for their Shareholders?PRNewsWire · Jul 29, 2026
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—PBCO, NEUP, SAFT, and PFLCGlobeNewsWire · Jul 28, 2026Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators.
| Date | Est. | Actual | |
|---|---|---|---|
| Sep 18, 2026 | -$0.56 | -$0.56 | Beat |
| Sep 2, 2026 | -$0.56 | -$0.56 | Beat |
| May 15, 2026 | -$0.56 | -$0.09 | Beat |
| Feb 17, 2026 | -$0.56 | -$0.77 | Miss |
| Nov 14, 2025 | -$1.33 | -$4.41 | Miss |
| Sep 29, 2025 | -$0.56 | -$5.79 | Miss |